Enliven Therapeutics Q3 net loss widens on higher R&D spend
ELVN•Enliven Therapeutics’ third-quarter net loss widened year over year as research and development expenses rose to $28 million from $18.2 million. The company ended the quarter with $884 million in cash and expects its runway to extend into 2030.
1. Higher research spending
Enliven Therapeutics reported a third-quarter net loss of $27.70 million, or $0.36 per basic share. Research and development expenses rose to $28 million from $18.2 million a year earlier, contributing to operating expenses of $36.05 million.
2. Trial plans and cash
The company said preparations for the ENABLE-2 pivotal Phase 3 trial contributed to higher operating expenses. Enliven reached FDA alignment on the trial design and expects to initiate the trial before the end of 2026. It ended the quarter with $884 million in cash and expects the funds to provide a runway into 2030.
